Department of Vascular and Endovascular Surgery, Ludwig-Maximilians-University Munich, Munich, Germany
Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus Technische Universität Dresden, Dresden, Germany.
J Am Heart Assoc. 2017 Nov 30;6(12):e006798. doi: 10.1161/JAHA.117.006798.
Clinical decision making in abdominal aortic aneurysms (AAA) relies completely on diameter. At this point, improved decision tools remain an unmet medical need. Our goal was to identify changes at the molecular level specifically leading up to AAA rupture.
Aortic wall tissue specimens were collected during open elective (eAAA; n=31) or emergency repair of ruptured AAA (rAAA; n=17), and gene expression was investigated using microarrays. Identified candidate genes were validated with quantitative real-time polymerase chain reaction in an independent sample set (eAAA: n=46; rAAA: n=18). Two gene sets were identified, 1 set containing 5 genes linked to terminal progression, that is, positively associated with progression of larger AAA, and with rupture (, , , , ), and a second set containing 5 genes exclusively upregulated in rAAA (, , , , ). Genes in both sets essentially associated with processes related to impaired tissue remodeling, such as angiogenesis and adipogenesis. In gene expression experiments we were able to show that upregulated gene expression for identified candidate genes is unique for AAA. Functionally, the selected upregulated factors converge at processes coordinated by the canonical HIF-1α signaling pathway and are highly expressed in fibroblasts but not inflammatory cells of the aneurysmatic wall. Histological quantification of angiogenesis and exploration of the HIF-1α network in rAAA versus eAAA shows enhanced microvessel density but also clear activation of the HIF-1α network in rAAA.
Our study shows a specific molecular fingerprint for terminal AAA disease. These changes appear to converge at activation of HIF-1α signaling in mesenchymal cells. Aspects of this cascade might represent targets for rupture risk assessment.
腹主动脉瘤(AAA)的临床决策完全依赖于直径。目前,改进的决策工具仍然是未满足的医疗需求。我们的目标是确定具体导致 AAA 破裂的分子水平变化。
在开放性择期(eAAA;n=31)或破裂性 AAA 紧急修复(rAAA;n=17)期间采集主动脉壁组织标本,并使用微阵列研究基因表达。在独立样本集中(eAAA:n=46;rAAA:n=18)使用定量实时聚合酶链反应验证了鉴定的候选基因。确定了两个基因集,一个包含 5 个与终末期进展相关的基因,即与较大 AAA 的进展和破裂呈正相关的基因(,,,,),另一个包含仅在 rAAA 中上调的 5 个基因(,,,,)。两个基因集的基因基本上与与组织重塑受损相关的过程相关,如血管生成和脂肪生成。在基因表达实验中,我们能够证明鉴定的候选基因的上调基因表达对于 AAA 是独特的。功能上,选定的上调因子集中在由经典 HIF-1α 信号通路协调的过程上,在成纤维细胞中高度表达,但不在动脉瘤壁的炎症细胞中表达。rAAA 与 eAAA 相比的血管生成的组织学定量和 HIF-1α 网络的探索表明微血管密度增加,但 rAAA 中的 HIF-1α 网络也明显激活。
我们的研究显示了终末期 AAA 疾病的特定分子特征。这些变化似乎集中在间充质细胞中 HIF-1α 信号的激活上。该级联的某些方面可能代表破裂风险评估的靶点。